

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: **SureNano Science Ltd.** (the "Issuer" or "SureNano").

Trading Symbol: **SURE**

Number of Outstanding Listed Securities: **42,008,799 common shares and 17,100,000 reserved for issuance**

Date: **April 7, 2026**

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Issuer pursued its business plan of developing a next-generation glucagon-like peptide ("GLP") and a patented therapeutic candidate designed to address obesity and metabolic disease with improved tolerability and delivery potential.

2. Provide a general overview and discussion of the activities of management.

During March 2026, management's principal activities consisted of reviewing the proposal received from the CRO for the IND-enabling studies for our GEP-44 peptide formulation, collaborating with LabCorp on GLP toxicology and pharmacology studies in various animal models, with quotes around \$2.1 million USD and study initiations planned for July/August (Shanghai) or April/May (US). The Issuer is actively reviewing the plan for its scientific merit, accuracy, and feasibility. Concurrently, along with the CRO, GenScript, the Issuer is developing lab-scale manufacturing protocols for GEP-44, starting with 1g production and progressing to a 3kg experimental scale. Additionally, the Issuer is working on finalizing the advisors' contracts.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

None.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture

agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

None.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None.

8. Describe the acquisition of new customers or loss of customers.

None.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

With the acquisition of GlucaPharm, the Issuer has obtained the licence giving its new subsidiary exclusive rights to develop Syracuse University's GEP-44, a GLP-1 pharmaceutical patent protected compound discovery and technology. GEP-44 is a novel compound that addresses diabetes and weight loss, similar to current in-market GLP-1s such as Ozempic®, Wegovy®, Mounjaro®, but targeting a no-needle administration method and superior tolerability, including reduced side effects most experienced by leading in-market drugs such as nausea and gastrointestinal issues. GEP-44 is a triple antagonist with strong preclinical results, patents filed, academic validation and market exploration underway.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None.

14. Provide details of any securities issued and options or warrants granted.

None.

15. Provide details of any loans to or by Related Persons.

None.

16. Provide details of any changes in directors, officers or committee members.

None.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The Issuer's business involves certain risks and uncertainties that are inherent to the Issuer's industry. For disclosure on risks related to an investment in the Issuer, please refer to the Issuer's prospectus under the title "Risk Factors", which is available on SEDAR+ at www.sedarplus.ca.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: April 7, 2026

Charles MaLette
Name of Director or Senior Officer

"Charles MaLette"
Signature

President, CEO and Director
Official Capacity

Issuer Details		
Name of Issuer SureNano Science Ltd.	For - Month End March 2026	Date of Report YYYY/MM/DD 2026/04/07
Issuer Address 1500 - 800 West Pender Street		
City/Province/Postal Code Vancouver, BC V6C 2V6	Issuer Fax No. N/A	Issuer Telephone No. (604) 428-5171
Contact Name Charles MaLette	Contact Position President, CEO, Director	Contact Telephone No. (604) 428-5171
Contact Email Address info@surenano.com	Web Site Address www.surenano.com	